DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Co.'s products include: DecCom G6®, which is designed to allow Co.'s transmitter to run an algorithm to generate a glucose value; Dexcom G7®, which is designed for all people with diabetes ages two years and older, giving access to a diabetes management solution; DexCom Share®, which is a remote monitoring system, provided for use with any existing Dexcom system; Dexcom Real-Time API, which expands connectivity and interoperability of the Dexcom CGM digital ecosystem; and Dexcom ONE®. The DXCM YTD return is shown above.
The YTD Return on the DXCM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether DXCM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DXCM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|